Xeris gets green light to take subcutaneous challenger to AbbVie drug into phase 2 ntaylor Tue, 12/20/2022 – 06:35 More: Xeris gets green light to take subcutaneous challenger to AbbVie drug into phase 2 Source: fierce
read moreAtara makes history with world-first nod for allogeneic T-cell therapy Ebvallo fkansteiner Mon, 12/19/2022 – 14:06 More: Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo Source: fierce
read moreAbbVie’s Vraylar, carrying $4B sales target, wins FDA label expansion in depression zbecker Mon, 12/19/2022 – 11:13 More: AbbVie's Vraylar, carrying B sales target, wins FDA label expansion in depression Source: fierce
read moreNovartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on fkansteiner Mon, 12/19/2022 – 10:53 More: Novartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on Source: fierce
read moreWith another FDA nod, Eagle’s Pemfexy gets up to speed with Lilly’s Alimta kdunleavy Mon, 12/19/2022 – 09:49 More: With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta Source: fierce
read moreDespite Imfinzi fail in lung cancer trial, AZ ‘encouraged’ by one result: exec esagonowsky Mon, 12/19/2022 – 09:06 More: Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals